File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0016-5085(07)60009-2
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Prevalence and prediction of gastrointestinal events in patients receiving a combination of aspirin plus clopidogrel
Title | Prevalence and prediction of gastrointestinal events in patients receiving a combination of aspirin plus clopidogrel |
---|---|
Authors | |
Issue Date | 2007 |
Publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro |
Citation | Digestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute, Washington, DC, 19-24 May 2007. In Gastroenterology, 2007, v. 132 n. 4, p. A-135 Abstract no. 916 How to Cite? |
Abstract | Introduction: The efficacy of the addition of clopidogrel to aspirin has been established but
this was associated with gastrointestinal complications in 1.3% of patients in study situation.
However, this has not been documented in real life. Aim: This retrospective study aimed
to determine the prevalence of upper gastrointestinal complication in real life situation. The
treatment effect of H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) was
also analysed, as compared to the control. Method: From Jan 2002 to Sept 2005, records
of all patients receiving dual anti-platelet therapy were analysed. The end-point was the
occurrence of symptomatic peptic ulcers or its complications. The last date of censor was
15 June 2006. Results: The patient group consisted of 664 patients (age 66.6±12.0 years).
Prophylactic H2RA and PPI was prescribed to 148 (22.2%) and 160(24.1%) patients,
respectively. Prior gastrointestinal bleeding was significantly more common in the PPI group
(16.3%) or the H2RA group (4.1%) than the control group (2.0%). After a follow-up of
4.6±5.2 months, end-point was reached in 28 (4.2%) patients (gastrointestinal bleed 26,
dyspepsia 2). After adjustment for the confounding covariates, the hazard ratio (95% confidence
interval) for primary end-point was 0.053 (0.006-0.219) for PPI and 0.324 (0.113-
0.925) for H2RA, as compared to control. Conclusion: In real life, the incidence of peptic
ulcer disease and gastrointestinal bleeding associated with dual aspirin plus clopdiogrel
therapy was 4.2%. Co-prescription with PPI or H2RA can significantly reduce the risk.
Hazard ratio (95% confidence interval) for primary and secondary end points : control, H2-
receptor antagonist and proton pump inhibitor. |
Persistent Identifier | http://hdl.handle.net/10722/102986 |
ISSN | 2023 Impact Factor: 25.7 2023 SCImago Journal Rankings: 7.362 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, AOO | en_HK |
dc.contributor.author | Ng, FH | en_HK |
dc.contributor.author | Chang, PCM | en_HK |
dc.contributor.author | Wong, SY | en_HK |
dc.contributor.author | Chu, WM | en_HK |
dc.contributor.author | Yuen, WC | en_HK |
dc.contributor.author | Lau, YK | en_HK |
dc.contributor.author | Cheung, TK | en_HK |
dc.contributor.author | Wong, BCY | en_HK |
dc.date.accessioned | 2010-09-25T20:52:55Z | - |
dc.date.available | 2010-09-25T20:52:55Z | - |
dc.date.issued | 2007 | en_HK |
dc.identifier.citation | Digestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute, Washington, DC, 19-24 May 2007. In Gastroenterology, 2007, v. 132 n. 4, p. A-135 Abstract no. 916 | en_HK |
dc.identifier.issn | 0016-5085 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/102986 | - |
dc.description.abstract | Introduction: The efficacy of the addition of clopidogrel to aspirin has been established but this was associated with gastrointestinal complications in 1.3% of patients in study situation. However, this has not been documented in real life. Aim: This retrospective study aimed to determine the prevalence of upper gastrointestinal complication in real life situation. The treatment effect of H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) was also analysed, as compared to the control. Method: From Jan 2002 to Sept 2005, records of all patients receiving dual anti-platelet therapy were analysed. The end-point was the occurrence of symptomatic peptic ulcers or its complications. The last date of censor was 15 June 2006. Results: The patient group consisted of 664 patients (age 66.6±12.0 years). Prophylactic H2RA and PPI was prescribed to 148 (22.2%) and 160(24.1%) patients, respectively. Prior gastrointestinal bleeding was significantly more common in the PPI group (16.3%) or the H2RA group (4.1%) than the control group (2.0%). After a follow-up of 4.6±5.2 months, end-point was reached in 28 (4.2%) patients (gastrointestinal bleed 26, dyspepsia 2). After adjustment for the confounding covariates, the hazard ratio (95% confidence interval) for primary end-point was 0.053 (0.006-0.219) for PPI and 0.324 (0.113- 0.925) for H2RA, as compared to control. Conclusion: In real life, the incidence of peptic ulcer disease and gastrointestinal bleeding associated with dual aspirin plus clopdiogrel therapy was 4.2%. Co-prescription with PPI or H2RA can significantly reduce the risk. Hazard ratio (95% confidence interval) for primary and secondary end points : control, H2- receptor antagonist and proton pump inhibitor. | - |
dc.language | eng | en_HK |
dc.publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro | en_HK |
dc.relation.ispartof | Gastroenterology | en_HK |
dc.title | Prevalence and prediction of gastrointestinal events in patients receiving a combination of aspirin plus clopidogrel | en_HK |
dc.type | Conference_Paper | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0016-5085&volume=132&issue=4&spage=A135&epage=&date=2007&atitle=Prevalence+and+prediction+of+gastrointestinal+events+in+patients+receiving+a+combination+of+aspirin+plus+clopidogrel.++Digestive+Disease+Week+2007,+Washington+DC,+USA,+19-24+May | en_HK |
dc.identifier.email | Chan, AOO: aoochan@hku.hk | en_HK |
dc.identifier.email | Ng, FH: ngfhong@HKUCC.hku.hk | en_HK |
dc.identifier.email | Chang, PCM: changcm@ha.org.hk | en_HK |
dc.identifier.email | Wong, SY: maggie10_18@yahoo.com | en_HK |
dc.identifier.email | Lau, YK: yklau@ha.org.hk | en_HK |
dc.identifier.email | Cheung, TK: cheungtingkin@yahoo.com | en_HK |
dc.identifier.email | Wong, BCY: bcywong@hku.hk | en_HK |
dc.identifier.authority | Wong, BCY=rp00429 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/S0016-5085(07)60009-2 | - |
dc.identifier.hkuros | 131415 | en_HK |
dc.identifier.volume | 132 | en_HK |
dc.identifier.issue | 4 | en_HK |
dc.identifier.spage | 135 | en_HK |
dc.identifier.issnl | 0016-5085 | - |